Cost-effectiveness of an early Cognitive Behavioral Treatment in work disability due to musculoskeletal disorders

ISRCTN ISRCTN17984927
DOI https://doi.org/10.1186/ISRCTN17984927
Secondary identifying numbers N/A
Submission date
06/06/2007
Registration date
27/06/2007
Last edited
27/10/2021
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Musculoskeletal Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Juan Angel Jover
Scientific

Rheumatology
Hospital Clinico San Carlos
Martin Lagos s/n
Madrid
28040
Spain

Study information

Study designRandomized controlled study.
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeNot Specified
Scientific titleCost-effectiveness of an early Cognitive Behavioral Treatment in work disability due to musculoskeletal disorders
Study acronymEarly CBT in TWD-MSD (Temporary Work Disability-MusculoSkeletal Disorders)
Study objectivesTo evaluate whether a Cognitive Behavioral Treatment (CBT), complementary to a rheumatologic specific program, offered to patients with poor evolution of work disability caused by musculoskeletal disorders (MSDs) is cost-effective.
Ethics approval(s)Ethics Committee of Clinical Investigation, Hospital Clínico San Carlos, approved on 30 June 2004 (ref: 0-04/139).
Health condition(s) or problem(s) studiedMusculoskeletal disorders-related temporary work disability
InterventionA psychologist will deliver CBT that is complementary to a rheumatologic specific program. One session lasts 45 minutes. The number of sessions is not previously fixed, and varies between 1 and a maximum of 8. The control group will receive standard care.
Intervention typeOther
Primary outcome measureEfficacy was defined as the differences between groups in the following (assessed for each participant 6 months after inclusion into the study):
1. Duration of all MSD-TWD episodes
2. Number of MSD-TWD episodes per patient
3. Number or relapses of MSD-TWD episodes
4. Duration or relapses of MSD-TWD episodes
5. Number and outcome of proposal for permanent work disability
Secondary outcome measuresCost measures
Overall study start date15/10/2004
Completion date15/04/2007

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants200
Key inclusion criteria1. Musculoskeletal disorders-related temporary work disability for at least 3 weeks
2. Admitted to the rheumatologic specialized care
Key exclusion criteriaPatients with more than 8 weeks MSD-related temporary work disability.
Date of first enrolment15/10/2004
Date of final enrolment15/04/2007

Locations

Countries of recruitment

  • Spain

Study participating centre

Rheumatology
Madrid
28040
Spain

Sponsor information

Musculoskeletal Disease Foundation and FREMAP Foundation
Research organisation

Ercon Consultores
Calle Jorge Juan 78
Madrid
28009
Spain

Website http://www.fremap.es/

Funders

Funder type

Hospital/treatment centre

Foundation for Biomedical Investigation (Fundación para la Investigación Biomédica, Hospital Clinico San Carlos) (Spain)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing planNot provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article 29/06/2009 27/10/2021 Yes No

Editorial Notes

27/10/2021: Publication reference added.